News
Public · Published
TD Cowen maintains Gilead Sciences at Buy, raises price target to $175 from $160
TD Cowen kept its Buy rating on Gilead Sciences and raised its price target to $175 from $160, a 9.4% increase. The new target implies 5.7% upside from the October 29 close of $165.61.
Published:
Updated:
What happened
TD Cowen kept its Buy rating on Gilead Sciences and raised its price target to $175 from $160, a 9.4% increase. The new target implies 5.7% upside from the October 29 close of $165.61.
Confirmed
Global impact / market context
A higher target means this analyst expects more share-price gain than before. Other recent targets run from $131 to $190, so views differ widely. The spread shows investors lack consensus on how much Gilead's future sales and profit are worth.
Analyst inference
Broker targets are opinions, not guarantees, and they can pull investor attention and money toward a stock. Widely spaced targets can make trading choppier as buyers and sellers weigh conflicting outlooks. One raised target alone rarely changes a company's actual cash flow.
Analyst inference
What to watch
- TD Cowen's $175 target is 5.7% above the October 29 close of $165.61, so watch whether the stock moves toward that level. Confirmed
- Gilead could report trial results or drug sales that justify higher targets, so watch company updates on its pipeline and revenue. Proposed
- If other analysts raise targets toward the $190 high, that could signal growing confidence and support demand for the shares. Analyst inference
Evidence
- Original source link unavailable